The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College ...

Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults ...

1,5 In this prespecified secondary analysis of the SELECT trial, semaglutide 2.4 mg reduced total events (first and subsequent) by 22% (MR 0.78; 95% CI 0.70–0.86; P<0.001), 1 reduced non-fatal ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...